Changes in Plasma Copeptin Levels during Hemodialysis: Are the Physiological Stimuli Active in Hemodialysis Patients?

• Published in: PloS one 2015-05, Vol.10 (5), p.e0127116-e0127116
• Main Authors: Ettema, Esmée M, Kuipers, Johanna, Assa, Solmaz, Bakker, Stephan J L, Groen, Henk, Westerhuis, Ralf, Gaillard, Carlo A J M, Gansevoort, Ron T, Franssen, Casper F M
• Format: Article
• Language: English
• Subjects: Aged; Argipressin; Blood; Blood Pressure; Blood Volume; Cardiovascular disease; Dependent variables; Diabetes mellitus; Dialysis; Female; Glycopeptides - blood; Health aspects; Hemodialysis; Humans; Hypertension; Internal medicine; Kidney diseases; Male; Medicine; Middle Aged; Mortality; Multivariate analysis; Natriuretic Peptide, Brain - blood; Nephrology; Observational studies; Osmolar Concentration; Patients; Peptide Fragments - blood; Peptides; Physiological aspects; Physiology; Plasma levels; Renal Dialysis; Sepsis; Sodium; Sodium - blood; Stimuli; Ultrafiltration; Vasopressin
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0127116

Plasma levels of copeptin, a surrogate marker for the vasoconstrictor hormone arginine vasopressin (AVP), are increased in hemodialysis patients. Presently, it is unknown what drives copeptin levels in hemodialysis patients. We investigated whether the established physiological stimuli for copeptin release, i.e. plasma osmolality, blood volume and mean arterial pressure (MAP), are operational in hemodialysis patients. One hundred and eight prevalent, stable hemodialysis patients on a thrice-weekly dialysis schedule were studied during hemodialysis with constant ultrafiltration rate and dialysate conductivity in this observational study. Plasma levels of copeptin, sodium, MAP, and blood volume were measured before, during and after hemodialysis. Multivariate analysis was used to determine the association between copeptin (dependent variable) and the physiological stimuli plasma sodium, MAP, excess weight as well as NT-pro-BNP immediately prior to dialysis and between copeptin and changes of plasma sodium, MAP and blood volume with correction for age, sex and diabetes during dialysis treatment. Patients were 63 ± 15.6 years old and 65% were male. Median dialysis vintage was 1.6 years (IQR 0.7-4.0). Twenty-three percent of the patients had diabetes and 82% had hypertension. Median predialysis copeptin levels were 141.5 pmol/L (IQR 91.0-244.8 pmol/L). Neither predialysis plasma sodium levels, nor NT-proBNP levels, nor MAP were associated with predialysis copeptin levels. During hemodialysis, copeptin levels rose significantly (p